Operating
Non-cash interest expense on liabilities related to the sale of future royalties and development funding
Alnylam Pharmaceuticals Non-cash interest expense on liabilities related to the sale of future royalties and development funding increased by 62.1% to $66.24M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 21.3%, from $54.63M to $66.24M. Over 3 years (FY 2021 to FY 2024), Non-cash interest expense on liabilities related to the sale of future royalties and development funding shows relatively stable performance with a 2.9% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
First reportedQ1 2018
Last reportedQ1 2026Apr 30, 2026
Metric ID:
operating_non_cash_interest_expense_on_sale_of_future_royaltiesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $28.84M | $30.18M | $29.37M | $27.7M | $27M | $24.92M | $24.58M | $25.28M | $26.37M | $27.27M | $27.64M | $31.57M | $29.54M | $30.73M | $35.3M | $54.63M | $16.81M | $40.86M | $66.24M |
| QoQ Change | — | +4.7% | -2.7% | -5.7% | -2.5% | -7.7% | -1.4% | +2.8% | +4.3% | +3.4% | +1.3% | +14.2% | -6.4% | +4.0% | +14.9% | +54.7% | -69.2% | +143.1% | +62.1% |
| YoY Change | — | — | — | — | -6.4% | -17.4% | -16.3% | -8.8% | -2.3% | +9.4% | +12.4% | +24.9% | +12.0% | +12.7% | +27.7% | +73.1% | -43.1% | +33.0% | +21.3% |
Range$16.81M – $66.24M
CAGR+20.3%
Avg YoY Growth+8.8%
Median YoY Growth+12.0%
Current Streak2 quarters growth
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding?
- Alnylam Pharmaceuticals (ALNY) reported non-cash interest expense on liabilities related to the sale of future royalties and development funding of $66.24M in Q1 2026.
- How has Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding changed year-over-year?
- Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding increased by 21.3% year-over-year, from $54.63M to $66.24M.
- What is the long-term trend for Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding?
- Over 3 years (2021 to 2024), Alnylam Pharmaceuticals's non-cash interest expense on liabilities related to the sale of future royalties and development funding has grown at a 2.9% compound annual growth rate (CAGR), from $116.56M to $127.13M.